Na2B12H11SH (BSH) in combination with systemic hyaluronidase: A promising concept for boron neutron capture therapy for glioblastoma

Neurosurgery

Volumn 39, Issue 2, 1996, Pages 321-326

  Haselsberger, Klaus ^a,b   Radner, Herbert ^a   Pendl, Gerhard ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b Universitatsklinik fur Neurochirurgie Innsbruck   (Austria)

Author keywords

Boron neutron capture therapy; Brain neoplasm; Glioblastoma; Hyaluronidase

Indexed keywords

HYALURONIDASE; UNCLASSIFIED DRUG; BORANE DERIVATIVE; BOROCAPTATE; HYALURONOGLUCOSAMINIDASE; RADIOSENSITIZING AGENT; THIOL DERIVATIVE;

ARTICLE; BIOACCUMULATION; BLOOD LEVEL; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; NEUTRON CAPTURE THERAPY; PRIORITY JOURNAL; TISSUE DISTRIBUTION; ADJUVANT THERAPY; ADULT; AGED; BIOAVAILABILITY; BLOOD BRAIN BARRIER; BRAIN TUMOR; CRANIOTOMY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHYSIOLOGY;

ADULT; AGED; BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; BOROHYDRIDES; BORON NEUTRON CAPTURE THERAPY; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; CRANIOTOMY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOBLASTOMA; HUMANS; HYALURONOGLUCOSAMINIDASE; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; SULFHYDRYL COMPOUNDS;

EID: 0030003304     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199608000-00016     Document Type: Article

References (23)

1. Barth RF, Soloway AH, Fairchild RG: Boron neutron capture therapy of cancer. Cancer Res 50:1061-1070, 1990.
2. Baumgartner G, Moritz A: Nebenwirkungen, in Baumgartner G, Moritz A (eds): Hyaluronidase: Anwendung in der Onkologie; Übersicht über experimentelle und klinische Daten. Wien, Springer, 1988, pp 63-67.
3. Baumgartner G, Horaczek A, Grunert P, Kitz K, Wunsch M: Hyaluronidase als Zusatz zur zytostatischen Chemotherapie bei Glioblastomen. Onkologie 10:100-103, 1987.
4. Beckenlehner K, Bannke S, Spruss T, Bernhardt G, Schonenberg H, Schiess W: Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo. J Cancer Res Clin Oncol 118:591-596, 1992.
5. Bertelli G, Dini D, Forno GB, Gozza A, Silvestro S, Venturini M, Rosso R, Pronzato P: Hyaluronidase as an antidote to extravasation of Vinca alkaloids: Clinical results. J Cancer Res Clin Oncol 120:505-506, 1994.
6. Dick SJ, Macchi B, Papazoglou S, Oldfield EH, Kornblith PJ, Smith BH, Gately MK: Lymphoid cell-glioma cell interaction enhances cell coat production by human gliomas: Novel suppressor mechanism. Science 220:739-742, 1983.
7. Gabel D: Safety and efficacy in boron neutron capture therapy, in Gabel D, Moss R (eds): Boron Neutron Capture Therapy: Toward Clinical Trials of Glioma Treatment. New York, Plenum Press, 1992, pp 7-14.
8. Deleted in proof.
9. 11SH (BSH) in patients with malignant glioma as precondition for boron neutron capture therapy (BNCT). Int J Radial Oncol Biol Phys 28:1175-1181, 1994.
10. 11SH. J Neurosurg 81: 741-744, 1994.
11. 11SH in patients with glioblastoma. Cancer Res 54:6318-6320, 1994.
12. Hatanaka H, Kamano S, Amano K, Hojo S, Sano K, Egawa S, Yasukochi H: Clinical experience of boron-neutron capture therapy for gliomas: A comparison with conventional chemoimmuno-radiotherapy, in Hatanaka H (ed): Boron Neutron Capture Therapy for Tumors. Niigata, Japan, Nishimura, 1986, pp 349-378.
13. Krohn J, Seland JH, Hovding G, Bertelsen T, Aasved H, Haugen OH: Retrobulbar anesthesia with and without hyaluronidase in extracapsular cataract surgery: A prospective, randomized, double-blind study. Acta Ophthalmol (Copenh) 71:791-795, 1993.
14. Lin Y, Mahan K, Lathrop WF, Myles DG, Primakoff P: A hyaluronidase activity of the sperm plasma membrane protein PH-20 enables sperm to penetrate the cumulus cell layer surrounding the egg. J Cell Biol 125:1157-1163, 1994.
15. McBride WH, Bard JBL: Hyaluronidase-sensitive halos around adherent cells: Their role in blocking lymphocyte-mediated cytolysis. J Exp Med 149:507-515, 1979.
16. Morris GM, Coderre JA, Hopewell JW, Micca PL, Nawrocky MM, Liu HB, Bywaters A: Response of the central nervous system to boron neutron capture irradiation: Evaluation using rat spinal cord model. Radiother Oncol 32:249-255, 1994.
17. Moss R: Current overview on the approach of clinical trials at Petten, in Gabel D, Moss R (eds): Boron Neutron Capture Therapy: Toward Clinical Trials of Glioma Treatment. New York, Plenum Press, 1992, pp 33-46.
18. Otersen B: Bindung, immunhistochemische Lokalisation und elektronenmikroskopische Darstellung von Mercaptoundecahy-drododecaborat (BSH) in Glioblastomen. Bremen, Universität Bremen, 1994 (dissertation).
19. Philpott DE: Changes in fine structure of the frog lung induced by substances altering transcapillary exchange. Exp Med Surg 23:288-314, 1965.
20. Robert AM, Godeau G: Action of proteolytic and glycolytic enzymes on the permeability of the blood-brain barrier. Biomed Biochim Acta 21:36-39, 1974.
21. Stragliotto G, Fankhauser H: Biodistribution of boron sulfhydryl for boron neutron capture therapy in patients with intracranial tumors. Neurosurgery 36:285-293, 1995.
22. Zänker KS, Trappe A, Blümel G: In-vitro resistance of cloned human glioma cells to natural killer activity of allogeneic peripheral lymphocytes. Br J Cancer 46:617-624, 1982.
23. Zülch KJ: Histological Typing of Tumours of the Central Nervous System. Geneva, World Health Organization, 1979.